| Tyler Raup, AUD | |
|
580 Ritchie Hwy, Suite I, Severna Park, MD 21146-3924 | |
| (410) 647-7795 | |
| (410) 315-8823 |
| Full Name | Tyler Raup |
|---|---|
| Gender | Male |
| Speciality | Qualified Audiologist |
| Experience | 9 Years |
| Location | 580 Ritchie Hwy, Severna Park, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932583051 | NPI | - | NPPES |
| 01382 | Other | MD | MD LICENSES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 01382 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Chesapeake Hearing Centers Inc | 0840243259 | 7 |
News Archive
Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Appriss Inc., a leading technology provider for risk assessment and analytics in public safety and healthcare, announced its partnership with The MetroHealth System in Ohio to fight drug abuse, diversion and addiction where it's needed most – at the prescribing level.
A new device to treat brain aneurysms with stents improves access to the blood vessels allowing endovascular neurosurgeons to offer the minimally invasive technique to patients with complex cases. Dr. Demetrius Lopes, an endovascular neurosurgeon at Rush University Medical Center, was the first in the U.S. to use the new delivery system, called the Neuroform EZ Stent System.
Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. Results showed that a once-daily dose of oral betrixaban, given to patients with non-valvular atrial fibrillation or atrial flutter and at least one risk factor for stroke, reduced the incidence of major and clinically relevant non-major (CRNM) bleeds compared to dose-adjusted warfarin.
› Verified 8 days ago
| Provider Name | Chesapeake Hearing Centers Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093850216 PECOS PAC ID: 0840243259 Enrollment ID: O20050225000294 |
News Archive
Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Appriss Inc., a leading technology provider for risk assessment and analytics in public safety and healthcare, announced its partnership with The MetroHealth System in Ohio to fight drug abuse, diversion and addiction where it's needed most – at the prescribing level.
A new device to treat brain aneurysms with stents improves access to the blood vessels allowing endovascular neurosurgeons to offer the minimally invasive technique to patients with complex cases. Dr. Demetrius Lopes, an endovascular neurosurgeon at Rush University Medical Center, was the first in the U.S. to use the new delivery system, called the Neuroform EZ Stent System.
Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. Results showed that a once-daily dose of oral betrixaban, given to patients with non-valvular atrial fibrillation or atrial flutter and at least one risk factor for stroke, reduced the incidence of major and clinically relevant non-major (CRNM) bleeds compared to dose-adjusted warfarin.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tyler Raup, AUD 580 Ritchie Hwy, Suite I, Severna Park, MD 21146-3924 Ph: (410) 647-7795 | Tyler Raup, AUD 580 Ritchie Hwy, Suite I, Severna Park, MD 21146-3924 Ph: (410) 647-7795 |
News Archive
Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Appriss Inc., a leading technology provider for risk assessment and analytics in public safety and healthcare, announced its partnership with The MetroHealth System in Ohio to fight drug abuse, diversion and addiction where it's needed most – at the prescribing level.
A new device to treat brain aneurysms with stents improves access to the blood vessels allowing endovascular neurosurgeons to offer the minimally invasive technique to patients with complex cases. Dr. Demetrius Lopes, an endovascular neurosurgeon at Rush University Medical Center, was the first in the U.S. to use the new delivery system, called the Neuroform EZ Stent System.
Portola Pharmaceuticals and Merck today announced the results of EXPLORE-Xa, a Phase 2 exploratory, dose finding study of betrixaban, an investigational oral direct Factor Xa inhibitor. Results showed that a once-daily dose of oral betrixaban, given to patients with non-valvular atrial fibrillation or atrial flutter and at least one risk factor for stroke, reduced the incidence of major and clinically relevant non-major (CRNM) bleeds compared to dose-adjusted warfarin.
› Verified 8 days ago
Chesapeake Hearing Centers Inc Audiologist Medicare: Medicare Enrolled Practice Location: 650 Ritchie Hwy Ste 104, Severna Park, MD 21146 Phone: 410-647-7795 Fax: 410-315-8823 | |
Abigail Ritinski, Llc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 811 Ritchie Hwy Ste 15, Severna Park, MD 21146 Phone: 410-980-6136 | |
Ms. Donnia Zack-williams, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 580 I Ritchie Hwy, Severna Park, MD 21146 Phone: 410-647-7795 Fax: 410-315-8823 | |
Jaclyn Bewick, AUD Audiologist Medicare: Medicare Enrolled Practice Location: 580 Ritchie Hwy, Suite I, Severna Park, MD 21146 Phone: 410-647-7795 Fax: 410-315-8823 | |
Cortney A Sperry, AUD Audiologist Medicare: Medicare Enrolled Practice Location: 580 Ritchie Hwy Ste I, Severna Park, MD 21146 Phone: 410-647-7795 Fax: 410-315-8823 | |
Dr. Caroline H Aland, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 580 Ritchie Hwy, Ste I, Severna Park, MD 21146 Phone: 410-647-7795 Fax: 410-315-8823 |